Testosterone Replacement Therapy: Who Qualifies and What to Expect

Introduction: Why the Conversation Around TRT Needs More Precision

Testosterone replacement therapy (TRT) is one of the most searched and most misunderstood topics in men’s health. Prescriptions in the United States grew from 7.3 million in 2019 to more than 11 million in 2024, yet the information surrounding TRT rarely keeps pace with the demand.

Most content falls into one of two camps. Some over-hypes testosterone as a performance enhancer or anti-aging shortcut. The rest buries every meaningful consideration under alarming risk language. Neither approach serves the man trying to make an informed decision.

This article takes a different premise: TRT is a medically prescribed treatment for a specific clinical condition called hypogonadism. It is not a lifestyle upgrade. What follows covers who actually qualifies, what a proper workup involves, what the evidence shows across key outcomes, what the 2025 FDA label update means in plain language, and what ongoing oversight requires. The goal is clarity, not persuasion.

What Testosterone Does, and What Happens When Levels Fall

Testosterone influences far more than libido. It supports muscle mass, bone density, red blood cell production, mood, cognitive function, insulin sensitivity, and energy regulation. When levels fall meaningfully, the effects are felt across the whole system.

Testosterone declines roughly 1% per year after age 30, meaning a man at 60 may carry about 30% less than he did at 30. This is not only an aging story, however. Population-level testosterone has been declining across generations since the late 1980s, independent of individual aging, driven by rising obesity, sedentary lifestyles, endocrine-disrupting chemicals such as BPA and phthalates, chronic stress, and poor sleep.

The prevalence is significant. Approximately 40% of American men over 45 have hypogonadism, rising to roughly 50% in men in their 80s. An estimated 30 to 50% of men with Type 2 diabetes or obesity are also affected. Low serum testosterone has even been independently associated with increased all-cause mortality in men with cardiovascular disease, which reframes it as a metabolic and longevity concern, not merely a quality-of-life one.

The Dual-Criteria Requirement: Why Labs Alone, or Symptoms Alone, Are Not Enough

A legitimate hypogonadism diagnosis requires both confirmed low serum testosterone and corresponding symptoms. Neither criterion alone is sufficient.

This matters because symptoms like fatigue, low libido, and brain fog are non-specific. They can stem from poor sleep, depression, thyroid dysfunction, or stress. Treating based on symptoms without confirmed labs is inappropriate. Conversely, a low lab value in a man without symptoms does not automatically warrant treatment.

The American Urological Association uses a total testosterone below 300 ng/dL (10.4 nmol/L) as the standard diagnostic cutoff, though this is a guideline rather than an absolute rule. TRT is not FDA-approved for age-related decline without an associated medical condition, and it is not indicated for bodybuilding, athletic performance, or anti-aging purposes alone. The dual-criteria requirement is a patient protection, not a bureaucratic hurdle.

The Diagnostic Workup: What a Proper Evaluation Actually Looks Like

Testosterone follows a diurnal rhythm, peaking between 7 and 10 AM. A single draw can miss natural variation, which is why two separate fasting morning blood draws on different days are standard. This reduces false positives and confirms a true deficiency rather than a one-off reading.

Beyond Total Testosterone: The Full Hormonal Picture

Only the unbound fraction of testosterone is biologically active. A man can show a “normal” total testosterone yet have functionally low levels if SHBG (sex hormone-binding globulin) is elevated. High SHBG, common with aging, liver conditions, and certain medications, binds more testosterone and reduces the free fraction. That is why measuring free or bioavailable testosterone and SHBG is essential.

LH and FSH, the pituitary signaling hormones, reveal whether the problem originates in the testes (primary hypogonadism, with high LH/FSH) or in the brain’s signaling (secondary hypogonadism, with low or normal LH/FSH). Prolactin is checked because elevated levels can suppress the system and may point to a treatable pituitary adenoma. Baseline PSA for men 40 and older, hematocrit, and a full metabolic panel complete the picture. This workup is what distinguishes a clinical diagnosis from a self-diagnosis based on a symptom quiz.

Primary vs. Secondary Hypogonadism: Why the Cause Matters

In primary hypogonadism, the testes cannot produce adequate testosterone despite normal or elevated signaling. Causes include Klinefelter syndrome, testicular injury, chemotherapy, and radiation.

In secondary hypogonadism, the pituitary or hypothalamus is not sending adequate signals. Causes include obesity, sleep apnea, pituitary tumors, opioid use, and chronic illness, many of which are potentially reversible. Addressing the underlying cause, such as significant weight loss or treating sleep apnea, may restore testosterone without TRT. Red Mountain’s metabolic framework is designed to address these root causes, positioning TRT as one tool within a broader approach rather than a standalone fix.

What TRT Actually Does: Evidence Graded by Strength

TRT has strong evidence for some outcomes and modest or mixed evidence for others. The greatest benefits are consistently seen in men with baseline testosterone below 300 ng/dL whose on-treatment levels are maintained between 500 and 800 ng/dL.

Strong Evidence: Sexual Function, Body Composition, and Bone Density

• Sexual function: TRT consistently and meaningfully improves sexual desire and erectile function in men with confirmed hypogonadism, one of the most robust findings across trials.
• Body composition: TRT increases lean body mass and reduces fat mass, confirmed by the T-Trials and multiple meta-analyses, though magnitude varies.
• Bone mineral density: The T-Trials found +6.7% lumbar spine BMD versus +0.8% for placebo at 12 months. Robust fracture-prevention evidence, however, still remains lacking.
• Insulin sensitivity: A TRAVERSE substudy (JAMA Internal Medicine, 2024) suggested TRT may reduce progression from prediabetes to Type 2 diabetes, a meaningful finding given the overlap between hypogonadism and metabolic disease.
• Vitality and mood: Improvements in energy and well-being are consistently reported, though harder to quantify.

Modest or Mixed Evidence: Strength and Physical Performance

Improvements in strength and physical performance are generally modest and heterogeneous across trials, varying by baseline status, age, formulation, dose, and duration. TRT is not a performance-enhancing drug for men with normal testosterone. For men with confirmed deficiency, restoring physiologic levels supports the conditions for muscle preservation, but TRT alone, without proper nutrition and activity, is not a body-transformation tool. This is where Red Mountain’s broader metabolic and lifestyle framework adds value.

The Safety Picture: What the Evidence Actually Shows in 2025 to 2026

This is neither a reassurance campaign nor a scare piece. Readers deserve both the good news and the areas requiring vigilance.

The TRAVERSE Trial and the 2025 FDA Label Update

The landmark TRAVERSE trial randomized 5,246 men aged 45 to 80 with confirmed hypogonadism and elevated cardiovascular risk to testosterone or placebo, following them for a median of about 33 months. The headline finding: testosterone was non-inferior to placebo for major adverse cardiovascular events, at 7.0% versus 7.3%. This does not mean TRT is risk-free; it means it did not meaningfully increase heart attack, stroke, or cardiovascular death in this population.

Based on this evidence, the FDA in 2025 removed the long-standing black-box cardiovascular warning, replacing it with a new warning about blood pressure elevation. In June 2026, HHS and the FDA issued further labeling updates clarifying that clinical trial data do not demonstrate worsening BPH symptoms in men with mild-to-moderate disease, though monitoring remains recommended for severe BPH. Supporting meta-analyses found similar all-cause mortality between TRT and placebo (RR 0.85; 95% CI 0.60 to 1.19) and no significant differences in CV mortality, MI, stroke, or heart failure. The FDA’s December 2025 Expert Panel on TRT signals that regulatory review is ongoing.

Areas Requiring Ongoing Vigilance

• Erythrocytosis (elevated hematocrit) is the most common dose-related effect. U.S. guidelines recommend withholding therapy above 50%; European guidelines use 54%.
• Arrhythmias and thromboembolic events: TRAVERSE found increased non-fatal arrhythmias (5.2% vs. 3.3%) and venous thromboembolic events, requiring individualized assessment.
• Prostate: TRAVERSE found no significant increase in prostate cancer (0.5% vs. 0.4%, p=0.87). PSA monitoring remains standard.
• Blood pressure: The new label warning reflects evidence of possible elevation in some men.

These are not reasons to avoid TRT. They are reasons it requires proper clinical oversight rather than a self-directed approach.

Who Should Not Start TRT: Absolute and Relative Contraindications

A practice that clearly explains who is not a candidate demonstrates clinical integrity. Absolute contraindications include active prostate cancer, male breast cancer, recent heart attack or stroke, uncontrolled erythrocytosis (hematocrit above 50%), and severe untreated sleep apnea.

Fertility is a critical relative contraindication. TRT suppresses the HPG axis, reducing LH and FSH and leading to oligospermia or azoospermia. This consideration is frequently omitted in other content yet is essential for men under 45. It is not an absolute barrier: sperm banking before treatment and adjunctive HCG or clomiphene can preserve sperm production. A 2024 BMC Endocrine Disorders study found roughly 90% of men regained normal sperm counts within 12 months of stopping TRT, especially with HCG or clomiphene support. This conversation must happen before treatment begins, as part of informed consent.

Delivery Methods: Matching the Formulation to the Patient

TRT is not one-size-fits-all. Delivery method affects hormonal stability, monitoring frequency, hematocrit risk, and lifestyle fit.

• Injections (IM or subcutaneous): Most common and cost-effective, given weekly or biweekly. They produce peak-and-trough fluctuations some men notice. Subcutaneous injection is increasingly preferred for comfort.
• Topical gels and creams: Applied daily for near-physiologic steady levels, but require attention to transfer risk to partners or children before drying.
• Subcutaneous pellets: Implanted in-office every 3 to 6 months for stable levels, though the dose cannot be adjusted once placed.
• Oral testosterone undecanoate: A newer formulation using lymphatic absorption to avoid older oral liver toxicity, taken twice daily with meals.

The right choice should be made collaboratively with a clinician, not based on convenience alone.

Ongoing Monitoring: What Treatment Requires Over Time

Starting TRT is the beginning of an ongoing monitoring relationship. Per AUA and Endocrine Society guidelines, total and free testosterone, hematocrit, PSA (men 40+), lipid panel, and metabolic markers should be assessed every 3 to 6 months in the first year, then annually once stable.

A PSA velocity above 0.4 ng/mL per year or an absolute PSA above 4.0 ng/mL triggers urology referral. Therapy should be withheld if hematocrit exceeds 50%. Blood pressure monitoring is now part of standard management per the updated FDA label. This structure is what separates a clinically supervised program from a loosely monitored one. Red Mountain’s model, built on more than 30 years of real-world outcomes and in-person clinical oversight, is designed to support patients across the full journey, not just the initial prescription.

TRT Within a Broader Metabolic and Hormonal Framework

TRT is one tool, not a standalone fix. The relationship between low testosterone and metabolic disease runs both ways: obesity, insulin resistance, sleep apnea, and inactivity all suppress testosterone. Addressing these factors can raise testosterone naturally and improve TRT outcomes when treatment is indicated.

Lifestyle optimization, including weight loss (particularly visceral fat reduction), resistance training, better sleep, stress management, and reduced exposure to endocrine-disrupting chemicals, can meaningfully support testosterone levels. For men with secondary hypogonadism driven by modifiable factors, metabolic correction may restore levels without TRT or reduce the required dose.

This is the logic behind Red Mountain’s care architecture. The Foundation stage (metabolic assessment, weight management, nutrition) creates the conditions in which the Function stage (hormone optimization, including TRT) works most effectively. These are sequential and complementary, not competing. With an estimated 40% of men under 40 expressing interest in testosterone supplementation, appropriate candidate selection matters more than ever, which is why diagnosis must come before demand.

Conclusion: The Right Question Is Not “Should I Try TRT?” It Is “Do I Qualify, and What Does Proper Care Look Like?”

TRT is a legitimate, evidence-supported treatment for confirmed hypogonadism. The operative word is confirmed. The diagnostic process exists to protect patients, not to create barriers.

That process means low labs and corresponding symptoms, evaluated through a thorough workup that includes free testosterone, SHBG, LH, FSH, prolactin, PSA, and hematocrit. The evidence is strong for sexual function, body composition, bone density, and insulin sensitivity; modest for strength and performance; and meaningfully updated on cardiovascular safety following TRAVERSE and the 2025 FDA label changes, alongside real risks that require monitoring. The fertility conversation remains non-negotiable for men who may want children. Properly managed, TRT is one powerful tool within a broader metabolic and hormonal framework. The goal is not to prescribe testosterone. It is to help men understand why they feel the way they do and address the root causes with the right combination of tools.

Is TRT Right for You? Start With the Right Evaluation

If the symptoms, questions, and uncertainty about whether testosterone levels are actually low sound familiar, a proper evaluation is the appropriate next step.

A Red Mountain consultation is a clinical conversation, not a sales pitch. It includes comprehensive labs, a thorough review of symptoms and health history, and an honest assessment of whether TRT is indicated and, if so, what a monitored program looks like. With more than 30 years of real-world patient outcomes, in-person clinical oversight, and a care model built to support patients from initial evaluation through long-term maintenance, the focus stays on understanding.

The goal of a first conversation is to get answers, not to start a prescription. When a patient is ready to understand what the body is actually signaling, that conversation is where it begins.